Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Cập nhật hướng dẫn S3 về chẩn đoán, phòng ngừa và điều trị bệnh loãng xương
Tóm tắt
Thông qua một mô hình đánh giá nguy cơ gãy xương mới, mục tiêu là giảm thiểu khoảng cách trong điều trị bệnh loãng xương. Bệnh nhân từ 70 tuổi trở lên nên được kiểm tra chẩn đoán bệnh loãng xương. Một ngưỡng rủi ro bổ sung sẽ cho phép bệnh nhân có nguy cơ gãy xương rất cao (≥ 10% trong 3 năm đối với gãy xương đùi và đốt sống) được điều trị bằng các chế phẩm osteoanabole. Việc sử dụng các chế phẩm osteoanabole yêu cầu phải có liệu pháp chống tái hấp thu tiếp theo trong quá trình điều trị. Việc bắt đầu một liệu pháp cụ thể cho bệnh loãng xương không nên bị trì hoãn do tỷ lệ sự kiện thấp gây ra bởi hoại tử xương hàm, thông qua một biện pháp phòng ngừa nha khoa. Để cải thiện mức độ tuân thủ điều trị, cần tìm kiếm các giải pháp cá nhân hóa dựa trên sự hợp tác giữa bệnh nhân, người thân và bác sĩ. Một cuộc khảo sát về sự ngã thường xuyên nên được thực hiện từ độ tuổi 70 trở lên, bao gồm cả bài kiểm tra Timed-up-and-go.
Từ khóa
#Osteoporose #Frakturrisiko #Therapieadhärenz #Chẩn đoán loãng xương #Điều trị hoại tử xương hàmTài liệu tham khảo
Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82. https://doi.org/10.1007/s11657-020-00871-9
Glüer C‑C, Engelke K, Thomasius F (2023) Das Konzept des DVO Frakturrisikorechners. Osteologie 32:123–132. https://doi.org/10.1055/a-2053-7047
van Geel TACM, van Helden S, Geusens PP et al (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102. https://doi.org/10.1136/ard.2008.092775
Harvey NC, Odén A, Orwoll E et al (2018) Falls predict fractures independently of FRAX probability: a meta-analysis of the osteoporotic fractures in men (mrOS) study. J Bone Miner Res 33:510–516. https://doi.org/10.1002/jbmr.3331
Ryg J, Rejnmark L, Overgaard S et al (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977–2001. J Bone Miner Res 24:1299–1307. https://doi.org/10.1359/jbmr.090207
van Staa TP, Leufkens HG, Abenhaim L et al (2005) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 20:1486–1493. https://doi.org/10.1359/jbmr.2005.20.8.1486
Wustrack R, Seeman E, Bucci-Rechtweg C et al (2012) Predictors of new and severe vertebral fractures: results from the HORIZON pivotal fracture trial. Osteoporos Int 23:53–58. https://doi.org/10.1007/s00198-011-1664-4
Kendler DL, Marin F, Zerbini CAF et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230–240. https://doi.org/10.1016/S0140-6736(17)32137-2
Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427. https://doi.org/10.1056/nejmoa1708322
Lindsay R, Scheele WH, Neer R et al (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024–2030. https://doi.org/10.1001/archinte.164.18.2024
McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397–1406. https://doi.org/10.1002/jbmr.3452
Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190–198. https://doi.org/10.1002/jbmr.3337
Tsourdi E, Zillikens MC, Meier C et al (2021) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106:264–281. https://doi.org/10.1210/clinem/dgaa756
Otto S, Ristow O (2022) Antiresorptiva-assoziierte Kiefernekrosen – ein Update. MKG-Chirurg 15:59–74. https://doi.org/10.1007/s12285-021-00347-w
Rupp M, Walter N, Pfeifer C et al (2021) Originalarbeit: Inzidenz von Frakturen in der Erwachsenenpopulation in Deutschland. Dtsch Ärztebl Int 118:665–669. https://doi.org/10.3238/arztebl.m2021.0238
Khan AA, Morrison A, Kendler DL et al (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom 20:8–24. https://doi.org/10.1016/j.jocd.2016.09.005
Nikolaus T, Kruse W, Bach M et al (1996) Elderly patients’ problems with medication. An in-hospital and follow-up study. Eur J Clin Pharmacol 49:255–259. https://doi.org/10.1007/BF00226324
Hadji P, Felsenberg D, Amling M et al (2014) The non-interventional bonviva intravenous versus alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int 25:339–347. https://doi.org/10.1007/s00198-013-2515-2
Reyes C, Tebe C, Martinez-Laguna D et al (2017) One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study. Osteoporos Int 28:2997–3004. https://doi.org/10.1007/s00198-017-4144-7
Larsson BAM, Johansson L, Johansson H et al (2021) The timed up and go test predicts fracture risk in older women independently of clinical risk factors and bone mineral density. Osteoporos Int 32:75–84. https://doi.org/10.1007/s00198-020-05681-w
Dautzenberg L, Beglinger S, Tsokani S et al (2021) Interventions for preventing falls and fall-related fractures in community-dwelling older adults: a systematic review and network meta-analysis. J Am Geriatr Soc 69:2973–2984. https://doi.org/10.1111/jgs.17375
Wang Q, Jiang X, Shen Y et al (2020) Effectiveness of exercise intervention on fall-related fractures in older adults: a systematic review and meta-analysis of randomized controlled trials. BMC Geriatr 20:322. https://doi.org/10.1186/s12877-020-01721-6
Ming Y, Zecevic AA, Hunter SW et al (2021) Medication review in preventing older adults’ fall-related injury: a systematic review & meta-analysis. Can Geriatr J 24:237–250. https://doi.org/10.5770/CGJ.24.478
Hauff J, Rottenkolber M, Oehler P et al (2023) Single and combined use of fall-risk-increasing drugs and fracture risk: a population-based case-control study. Age Ageing. https://doi.org/10.1093/ageing/afad079
Deutz NEP, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, Cederholm T, Cruz-Jentoft A, Krznaric Z, Nair KS, Singer P, Teta D, Tipton K, Calder PC (2012) Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN expert. Group 100:130–134. https://doi.org/10.1016/j.clnu.2014.04.007.Protein
Wong RMY, Wong H, Zhang N et al (2019) The relationship between sarcopenia and fragility fracture—a systematic review. Osteoporos Int 30:541–553. https://doi.org/10.1007/s00198-018-04828-0
Groenendijk I, den Boeft L, van Loon LJC, de Groot LCPGM (2019) High versus low dietary protein intake and bone health in older adults: a systematic review and meta-analysis. Comput Struct Biotechnol J 17:1101–1112. https://doi.org/10.1016/j.csbj.2019.07.005
AWMF (2023) S3-Leitlinie „Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ)“ (AWMF-Register-Nr. 007-091). https://www.awmf.org